감염증 치료제 시장 규모, 점유율, 동향 분석 보고서 : 감염증별, 약물 종류별, 유통 채널별, 지역별, 부문별 예측(2025-2030년)

Infectious Disease Therapeutics Market Growth & Trends:

The global infectious disease therapeutics market size is expected to reach USD 283.91 billion by 2030, registering a CAGR of 3.5% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by increasing number of Human Immunodeficiency Virus (HIV), Human Papillomavirus (HPV), TB, and hepatitis cases globally.

Government and private organizations are investing heavily in the healthcare sector to prevent, diagnose, and treat infectious diseases; rising investments for development of new drugs to treat infectious diseases, and increasing number of initiatives for creating awareness about these conditions are expected to boost the market during the forecast period. Furthermore, increasing number of patent expirations and entry of generic drugs in the market are expected to increase the demand for infectious disease therapeutics due to their low prices.

In addition, availability of reimbursement for diagnosis & treatment of these infections and free distribution of drugs by manufacturers in regions with high incidence of these diseases are factors further expected to propel the market growth. However, low penetration rate of anti-infective and availability of large number of counterfeit drugs are expected to restraint the market growth during the forecast period.

North American market held the largest share in 2016. Presence of large number of manufacturers, favorable reimbursement scenario, and increasing healthcare expenditure are major factors responsible for the largest share held by this region. However, Asia Pacific is likely to grow at the highest rate between 2017 and 2025. High prevalence of infectious diseases; improving economic conditions in Asian countries, rising government initiatives to increase the adoption of treatments for infectious diseases, and rising funding activities are factors that can be attributed for the highest growth rate of this region during the forecast period.

Infectious Disease Therapeutics Market Report Highlights:

• Viral infections dominated the market with a 42.58% share in 2024. The parasitic infections segment is the fastest-growing market, driven by increasing prevalence, rising drug resistance, and global health initiatives targeting malaria, leishmaniasis, and schistosomiasis.
• Vaccines dominated the anti-infective agents market with a 32.75% share in 2024, driven by rising disease prevalence, growing awareness, and strong government immunization programs. The antiparasitic drugs segment is experiencing significant growth due to the rising prevalence of malaria, leishmaniasis, and other parasitic infections.
• Hospital pharmacies dominated the market with a revenue share of 52.19% in 2024, driven by the rising number of hospitalizations globally.The other pharmacy segment is experiencing rapid growth due to the increasing adoption of online pharmacies, which enhance accessibility and convenience for infectious disease therapeutics.
• North America holds a leading position in the 2024 infectious disease therapeutics market, accounting for 38.09% of the global share. The infectious disease therapeutics market in Asia Pacific is expanding due to the rising prevalence of bacterial and viral infections and improving healthcare infrastructure.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Infection
  • 1.2.2. Drug Class
  • 1.2.3. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Infectious Disease Therapeutics Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing incidence of infectious diseases
    • 3.2.1.2. Increasing incidence of infectious diseases
    • 3.2.1.3. Rising initiatives for the awareness of infectious diseases
  • 3.2.2. Market Restraint Analysis
• 3.3. 3.3.1 Emergence of resistance to infectious disease therapeutic drugs and adverse effects associated with them
• 3.4. Business Environment Analysis
  • 3.4.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.4.1.1. Supplier Power
    • 3.4.1.2. Buyer Power
    • 3.4.1.3. Substitution Threat
    • 3.4.1.4. Threat of New Entrants
    • 3.4.1.5. Competitive Rivalry
  • 3.4.2. PESTLE Analysis
  • 3.4.3. Pipeline Analysis

Chapter 4. Infectious Disease Therapeutics Market: Infections Business Analysis

• 4.1. Infections Market Share, 2024 & 2030
• 4.2. Infections Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Infections, 2018 to 2030 (USD Million)
• 4.4. Bacterial Infections
  • 4.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 4.5. Viral Infections
  • 4.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.5.2. Human Immunodeficiency Virus (HIV/AIDS)
    • 4.5.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.5.3. Hepatitis (Hepatitis B, Hepatitis C)
    • 4.5.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.5.4. Influenza
    • 4.5.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.5.5. Others
    • 4.5.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 4.6. Fungal Infections
  • 4.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 4.7. Parasitic Infections
  • 4.7.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 5. Infectious Disease Therapeutics Market: Drug Class Business Analysis

• 5.1. Drug Class Market Share, 2024 & 2030
• 5.2. Drug Class Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
• 5.4. Antibacterials
  • 5.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 5.5. Antivirals
  • 5.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 5.6. Antifungals
  • 5.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 5.7. Antiparasitic Drugs
  • 5.7.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 5.8. Vaccines
  • 5.8.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 5.9. Others
  • 5.9.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 6. Infectious Disease Therapeutics Market: Distribution Channel Business Analysis

• 6.1. Distribution Channel Market Share, 2024 & 2030
• 6.2. Distribution Channel Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
• 6.4. Hospitals Pharmacies
  • 6.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 6.5. Retail Pharmacies
  • 6.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 7. Infectious Disease Therapeutics Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 7.4. North America
  • 7.4.1. North America Infectious Disease Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Target Disease Prevalence
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. Reimbursement Framework
    • 7.4.2.5. U.S. Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Target Disease Prevalence
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Reimbursement Framework
    • 7.4.3.5. U.S. Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Target Disease Prevalence
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. Reimbursement Framework
    • 7.4.4.5. Mexico Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Europe
  • 7.5.1. Europe Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Target Disease Prevalence
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Reimbursement Framework
    • 7.5.2.5. UK Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Target Disease Prevalence
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Reimbursement Framework
    • 7.5.3.5. Germany Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Target Disease Prevalence
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. Reimbursement Framework
    • 7.5.4.5. France Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Target Disease Prevalence
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. Reimbursement Framework
    • 7.5.5.5. Italy Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Target Disease Prevalence
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. Reimbursement Framework
    • 7.5.6.5. Spain Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.7. Denmark
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Target Disease Prevalence
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Reimbursement Framework
    • 7.5.7.5. Denmark Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.8. Sweden
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Target Disease Prevalence
    • 7.5.8.3. Regulatory Framework
    • 7.5.8.4. Reimbursement Framework
    • 7.5.8.5. Sweden Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.9. Norway
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Target Disease Prevalence
    • 7.5.9.3. Regulatory Framework
    • 7.5.9.4. Reimbursement Framework
    • 7.5.9.5. Norway Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Target Disease Prevalence
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Reimbursement Framework
    • 7.6.2.5. Japan Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Target Disease Prevalence
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Reimbursement Framework
    • 7.6.3.5. China Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Target Disease Prevalence
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Reimbursement Framework
    • 7.6.4.5. India Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.5. Australia
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Target Disease Prevalence
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Reimbursement Framework
    • 7.6.5.5. Australia Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.6. South Korea
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Target Disease Prevalence
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. Reimbursement Framework
    • 7.6.6.5. South Korea Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Target Disease Prevalence
    • 7.6.7.3. Regulatory Framework
    • 7.6.7.4. Reimbursement Framework
    • 7.6.7.5. Thailand Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Target Disease Prevalence
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Reimbursement Framework
    • 7.7.2.5. Brazil Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Target Disease Prevalence
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Reimbursement Framework
    • 7.7.3.5. Argentina Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.8. Middle East and Africa
  • 7.8.1. Middle East and Africa Infectious Disease Therapeutics Market Estimates and Forecasts, 2017 - 2030 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Target Disease Prevalence
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. Reimbursement Framework
    • 7.8.2.5. South Africa Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Target Disease Prevalence
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. Reimbursement Framework
    • 7.8.3.5. Saudi Arabia Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Target Disease Prevalence
    • 7.8.4.3. Regulatory Framework
    • 7.8.4.4. Reimbursement Framework
    • 7.8.4.5. UAE Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Target Disease Prevalence
    • 7.8.5.3. Regulatory Framework
    • 7.8.5.4. Reimbursement Framework
    • 7.8.5.5. Kuwait Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Overview
• 8.2. Company Market Position Analysis
• 8.3. Company Categorization
• 8.4. Strategy Mapping
• 8.5. Company Profiles/Listing
  • 8.5.1. Pfizer Inc.
    • 8.5.1.1. Overview
    • 8.5.1.2. Financial Performance
    • 8.5.1.3. Infection Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. AbbVie.
    • 8.5.2.1. Overview
    • 8.5.2.2. Financial Performance
    • 8.5.2.3. Infection Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. Gilead Sciences, Inc.
    • 8.5.3.1. Overview
    • 8.5.3.2. Financial Performance
    • 8.5.3.3. Infection Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. Bristol-Myers Squibb
    • 8.5.4.1. Overview
    • 8.5.4.2. Financial Performance
    • 8.5.4.3. Infection Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. Merck & Co., Inc.
    • 8.5.5.1. Overview
    • 8.5.5.2. Financial Performance
    • 8.5.5.3. Infection Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. Sandoz International GmbH
    • 8.5.6.1. Overview
    • 8.5.6.2. Financial Performance
    • 8.5.6.3. Infection Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. B. Braun SE
    • 8.5.7.1. Overview
    • 8.5.7.2. Financial Performance
    • 8.5.7.3. Infection Benchmarking
    • 8.5.7.4. Strategic Initiatives
  • 8.5.8. Xellia Pharmaceuticals
    • 8.5.8.1. Overview
    • 8.5.8.2. Financial Performance
    • 8.5.8.3. Infection Benchmarking
    • 8.5.8.4. Strategic Initiatives
  • 8.5.9. Mankind Pharma
    • 8.5.9.1. Overview
    • 8.5.9.2. Financial Performance
    • 8.5.9.3. Infection Benchmarking
    • 8.5.9.4. Strategic Initiatives
  • 8.5.10. Bayer AG
    • 8.5.10.1. Overview
    • 8.5.10.2. Financial Performance
    • 8.5.10.3. Infection Benchmarking
    • 8.5.10.4. Strategic Initiatives
  • 8.5.11. AstraZeneca
    • 8.5.11.1. Overview
    • 8.5.11.2. Financial Performance
    • 8.5.11.3. Infection Benchmarking
    • 8.5.11.4. Strategic Initiatives
  • 8.5.12. Boehringer Ingelheim International GmbH.
    • 8.5.12.1. Overview
    • 8.5.12.2. Financial Performance
    • 8.5.12.3. Infection Benchmarking
    • 8.5.12.4. Strategic Initiatives
  • 8.5.13. Novartis AG
    • 8.5.13.1. Overview
    • 8.5.13.2. Financial Performance
    • 8.5.13.3. Infection Benchmarking
    • 8.5.13.4. Strategic Initiatives
  • 8.5.14. F. Hoffmann-La Roche Ltd
    • 8.5.14.1. Overview
    • 8.5.14.2. Financial Performance
    • 8.5.14.3. Infection Benchmarking
    • 8.5.14.4. Strategic Initiatives